Table 1.
Summary of the use of 5 dual nucleoside reverse-transcriptase inhibitor (NRTI) regimens, based on the first treatment course for each regimen.
| Cohort, regimen | Ever followed a regimen, no. (%) of subjects |
Also received a PI, % of subjects |
Also received an NNRTI, % of subjects |
Treatment initiation date, median (IQR) |
Duration of regimen, median (IQR), months |
Age at start of regimen, median (IQR), years |
|---|---|---|---|---|---|---|
| Fulla (n = 2233) | ||||||
| ZDV/3TC | 1336 (60) | 32 | 9 | Mar 1997 (Aug 1996–Jan 1998) | 12.4 (5.5–26.5) | 4.9 (1.8–7.5) |
| ZDV/ddI | 1022 (46) | 9 | 8 | Aug 1995 (Nov 1994–May 1996) | 17.0 (8.3–31.4) | 3.7 (1.5–6.4) |
| d4T/3TC | 1154 (52) | 67 | 19 | Mar 1998 (Jun 1997–Sep 1999) | 19.9 (6.4–49.3) | 6.0 (3.2–8.7) |
| d4T/ddI | 772 (35) | 59 | 23 | Nov 1998 (Aug 1997–Jun 2000) | 15.1 (5.9–35.1) | 6.4 (3.6–9.1) |
| ddI/3TC | 258 (12) | 40 | 14 | Jul 1997 (Oct 1996–Oct 2000) | 9.0 (3.0–20.6) | 6.6 (3.7–9.9) |
| Laboratoryb (n = 1553) |
||||||
| ZDV/3TC | 584 (38) | 42 | 13 | Apr 1997 (Sep 1996–Nov 1998) | 23.0 (11.8–41.7) | 5.2 (1.7–7.9) |
| ZDV/ddI | 386 (25) | 15 | 12 | Sep 1995 (Nov 1994–Jun 1996) | 25.0 (14.9–51.7) | 4.3 (1.9–7.0) |
| d4T/3TC | 688 (44) | 73 | 23 | Jul 1998 (Aug 1997–May 2000) | 40.5 (18.9–65.1) | 6.4 (3.4–9.0) |
| d4T/ddI | 439 (28) | 63 | 24 | Jun 1999 (Feb 1998–Jan 2001) | 27.6 (13.8–55.4) | 6.6 (3.8–9.2) |
| ddI/3TC | 118 (8) | 53 | 16 | Mar 2000 (Dec 1996–Aug 2002) | 17.1 (8.3–32.4) | 8.0 (6.0–10.6) |
NOTE. d4T, stavudine; ddI, didanosine; IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; 3TC, lamivudine; ZDV, zidovudine.
a
All age-eligible subjects who met the study criteria described in the Methods section.
b
The subset of subjects monitored for laboratory test abnormalities, defined as having ≥1 targeted laboratory evaluation while receiving the dual NRTI regimen of interest (or in the month after stopping therapy).